AZA+: A multi-site phase ½ dose escalation/expansion trial combining azacitidine and defactinib for high-risk myelodysplastic syndrome patients who fail to respond to azacytidine alone.

  • Pimanda, John (Primary Chief Investigator (PCI))
  • Polizzotto, Mark N. (Chief Investigator (CI))
  • Hertzberg, Mark S. (Chief Investigator (CI))
  • Wei, Andrew (Chief Investigator (CI))
  • Dawson, Mark A. (Chief Investigator (CI))
  • Lock, Richard B. (Chief Investigator (CI))
  • Unnikrishnan, Ashwin (Chief Investigator (CI))
  • Olivier, Jake (Chief Investigator (CI))
  • Fong, Chun Yew (Chief Investigator (CI))
  • Campbell, Peter (Chief Investigator (CI))

Project: Research

Project Details

StatusActive
Effective start/end date1/06/20 → 31/05/25